Positives

• Patients with moderate COVID-19 on favipiravir commonly clear virus within about a week and feel meaningfully better by two weeks, the kind of viral suppression Long COVID patients hope will reduce persistence PMC.
• Patients with non-severe COVID-19 on favipiravir commonly avoid disease progression at higher rates than untreated peers Scientific Reports.
• Patients pursuing favipiravir generally have to source it through Russian or Japanese pharmacies because it is not FDA-approved in the United States International Journal of Infectious Diseases.

Negatives

• No published randomized trial has yet tested favipiravir as a treatment for established Long COVID rather than acute infection, leaving its role for persistent post-viral symptoms entirely speculative PMC.
  
  

Hurdles & Side Effects

• Favipiravir is approved in Japan, Russia, and several other countries but not in the US or UK, so American Long COVID patients pursuing it must rely on international sourcing or research-trial participation ScienceDirect.